Who is sponsoring NCT05590000?

NCT05590000 is sponsored by Abbott Medical Devices.

What drugs are being tested in NCT05590000?

Interventions in NCT05590000: Gemini SCS neuromodulation system.

What condition does NCT05590000 study?

NCT05590000 studies Chronic Pain.

Is NCT05590000 still recruiting?

NCT05590000 is currently completed. Last updated 24 October 2023.

Are results published for NCT05590000?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-10-24 · How we verify

NCT05590000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Gemini Rechargeable Spinal Cord Stimulation (SCS) System

Completed NA Results posted Last updated 24 October 2023

What this trial tests

NA trial testing Gemini SCS neuromodulation system in Chronic Pain in 25 participants. Completed in 17 February 2023.

Timeline

20 September 2022

Primary endpoint
19 January 2023

17 February 2023

Quick facts

Lead sponsor	Abbott Medical Devices
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	25
Start date	20 September 2022
Primary completion	19 January 2023
Estimated completion	17 February 2023
Sites	6 locations across Australia

Drugs / interventions tested

Gemini SCS neuromodulation system

Conditions studied

Chronic Pain — all drugs for Chronic Pain →

Sponsor

Abbott Medical Devices — full company profile →

Who can join

18 and older, any sex, with Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Confirmatory Safety Endpoint: The Rate of Serious Adverse Events Related to the Investigational IPG and/or Charging System Primary · At 6 weeks (30-45 days) follow-up post implant

The rate of serious adverse events adjudicated as related to the investigational IPG and/or charging system will be assessed.

Group	Value	95% CI
Gemini Rechargeable Spinal Cord Stimulation (SCS) System	0

Adverse events — posted to ClinicalTrials.gov

Time frame: 6 weeks after the permanent implant procedure. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Gemini Rechargeable Spinal Cord Stimulation (SCS) System

Serious: 0/24 (0%)

Deaths: 0/24

Other adverse events (1 terms — click to expand)

Reaction	System	Gemini Rechargeable Spinal…
CEREBROSPINAL FLUID LEAKAGE	Nervous system disorders	—

Data from ClinicalTrials.gov NCT05590000 adverse events section.

Sponsor's own description

The aim of this pre-market, prospective, single-arm, non-randomized, open-label, multi-center clinical study is to collect confirmatory data to show that the Gemini SCS neurostimulation system functions as intended in a clinical setting.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Pain

Currently open trials in the same condition.

NCT07491549 — The Effect of Pain Education Group Therapy and Its Impact on Chronic Pain, Kinesiophobia, and Physical Activity · NA · recruiting
NCT07425691 — SPACE for Youth With Chronic Pain · recruiting
NCT07103135 — Optimizing Accelerated TMS for Chronic Pain With Thompson Sampling · Phase 1 · recruiting
NCT06219408 — CIH Stepped Care for Co-occurring Chronic Pain and PTSD · NA · recruiting
NCT07270406 — Healthy Behaviors for Insomnia Prevention in People With HIV and Ongoing Pain · NA · recruiting

Other Abbott Medical Devices trials

Trials by the same sponsor.

NCT07421076 — Grid eXplore Mapping Study · NA · recruiting
NCT07509658 — TriClip Japan Post-Approval Study · recruiting
NCT07361445 — Agilis RF TSP Early Feasibility Study · NA · recruiting
NCT07373353 — A Clinical Evaluation of AMJ-401 · NA · recruiting
NCT07217392 — Left Bundle Branch Area Pacing (LBBAP) PMCF Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05590000 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abbott Medical Devices
Last refreshed: 24 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05590000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing